Two Labs Blog

Two Labs Blog

Two Labs a Best Place to Work in Central Ohio

Michael Rowe Joins Two Labs as DSCSA (Serialization) Compliance Services Manager

What manufacturers need to know about Minnesota House Bill 400

New regulation requirements impacting your license

Doug Troy Joins Two Labs as New Chief Operating Officer

Two Labs Joins Global Celebration of Rare Disease Day

Current and Future Oncology Management in the United States

Innovative Access Agreements

Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

Two Labs Acquires Pennside Partners Ltd.

Everything You Need to Know About the DSCSA in 2018

Comparison of US and EU approaches to Oncology Management

Key Learnings on Pathways of Care

How a Trade Commercialization Team Makes Licensing Easier

Two Labs Hires Anita Dopkosky as Vice President of Specialty Pharmacy

Two Labs Acquires MKO Global Partners

How DSCSA Changes the Licensing Landscape for Third-Party Logistics

The Basics of Licensing: In & Out, Drug, & Facility

3 Entities That Can Change Your State Licensing Strategy

Consequences Pharmaceutical Companies Can Face for not Carrying the Correct State License and Being Noncompliant

Why Compendia is More Than Just a Price Book

Where do your Sales Reps turn when they have EHR issues?

Two Labs Marketing is Changing Its Name

Targeted agents indicated for autoimmune diseases

MKO Minute – Rise of Gene Therapy

Will lower cost therapies take share from legacy treatments?

Management and Budget Impact

7 Top Pharma Trends for 2017

MKO Minute – When Cures Become Commodities

Medical 3D Printing Breakthroughs Keep on Coming

Prescription Drugs: To Import or Not to Import?

NHS England Overhauls Access to Cancer Treatments

T-Cell Immunotherapy Market Predicted To Grow

British Pharma Industry Faces Challenges Post-Brexit

Is 3D Printing The Next Big Thing In Pharma?

Wearable Health Monitors & Apps-Transforming Health Care Delivery

Drug Development Clinical Trial Data – Public or Private?

Is Maine Right About Importing Prescription Drugs?

New Cancer Drugs Fuel Debate over Drug Testing Process

Adherence to Drug Regimens: Implications for Drug Developers

Is NICE Denying Patients the Best Treatments Available Today?

Do We Need Phase III Randomized Controlled Trials for EVERYTHING?

Defining Success in Clinical Trials: Is Learning Something Enough?

Breakthrough Therapy Opens Door to Streamlined Drug Development

Pharmaceutical Marketing Cutbacks, Doctors Getting Squeezed

Momentum for Biosimilars is Building. What’s Next?

Molecular Testing in Trouble from Medicare. Who’s on First?

Will Oncology and Pathology Unite on Molecular Testing?

NCI Improvements: Drug Development Opportunity for Pharma and Biotech

Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers

ASCO GU: Heads-Up for Biotech Drug Development in Kidney Cancer

FDA-Mixed Response to Proposed Faster Drug Development Pathway

FDA to Consider Faster Drug Development via Smaller Clinical Trials

ASCO GI Preview - Heads Up for GI Cancer Drug Development

Breast Cancer Drug Development - Targeting HER2 Activating Mutations

Welcome to Pharma & Biotech Today